Free Bio-Nano-MEMS Technology Talks -- TFUG Meeting June 17; San Jose

Jim McVittie mcvittie at cis.Stanford.EDU
Mon Jun 15 14:16:15 PDT 2009

( <> )

FREE ADMISSION-No need to register, just show up!!

TOPIC:  Bio-Nano-MEMS Technology

Meeting Date:   June 17, 2009

EARLY START TIME:   1:30 - 5:00 pm

Location: SEMI Global Headquarters

    Seminar Rooms 1 & 2

    3081 Zanker Road

    San Jose, CA 95134
    **Park in front or behind the 
    vacant building across from SEMI**

Co-Chairs:   Roc Blumenthal, roc at

                    Hok-kin Choi, Hokkin.choi at

                    Connie Wang, connie_wang at


1:30 - 1:35  Welcome/Announcements

1:35-2:05 "Development of Nano Biosensors for Diverse Applications" Dr.
M. Meyyappan, NASA Ames Research Center, m.meyyappan at 

Abstract:  Biosensors are needed in biomedical, water quality
monitoring, agricultural and food quality testing, environmental
monitoring, pathogen detection, general lab-on-a-chip needs and related

Detection of gases or vapors may rely on intelligent pattern recognition
approach using a sensor array. But biosensors in a fluidic environment
should preferably work using a "lock and key" approach wherein a probe
molecule, selected a priori for the target of interest,  is attached to
an electrode or a device.  Upon hybridization, either electrical or
electrochemical signal can be measured, though most biosensors to date
have relied on optical signal transduction. Electronic approach is more
amenable to wafer scale fabrication as well as for integration with
microfluidics for sample delivery.  This brief talk outlines general
requirements and presents some examples from our lab. The author
acknowledges contributions from Hua Chen, Prabhu Arumugam, Jun Li, Y. Lu
and Jing Li.

2:05 - 2:35 "Biomimeticaly Engineered Nanomedical Systems", Demir Akin,
DVM, Ph.D,

Deputy Director, Center for Cancer Nanotechnology Excellence focused on
Therapy Response (CCNE-TR), School of Medicine, Department of Radiology,
Stanford University, Demir.Akin at

Abstract:  Dramatic changes occur in the material properties and
unexpected behaviors emerge as the material dimensions approach
nanometer size. Biological systems capitalize on these nanophenomena in
the forms of naturally evolved life sustaining functions. Towards the
realization of personalized medicine, nanotechnology promise amazing
possibilities which can all be collectively named under Nanomedicine. In
this talk, I will give some examples of these natural nanodevices and
also some of our own man-made biomimetic micro to nanoscale nanomedical
devices.  As a highly cohesive, interdisciplinary group of researchers,
we have been designing, fabricating and studying diagnostic and
therapeutic applications of various BioMEMS and BioNEMS-based devices
ranging from silicon-based nanocantilevers, nanopores to nanowires as
biosensors, active biomimetic nanodevices that utilize phi29 DNA
packaging machinery for  novel biomolecule sensing, capture and sorting
functions to novel multifunctional nanodevices utilizing microbal
robotics (microbotics) for targeted delivery and controlled drug
release. Systems level integration of a mixture of these modalities, as
Lab-on-a Chip devices, will also be presented as well as some
nanomaterials biocompatibility studies. Brief but specific examples from
each of these Nanomedicine domains will be given in the hopes that this
talk will lead us to explore future collaborative "nano-possibilities"
under the umbrella of Stanford's Center for Cancer Nanotechnology

2:35-3:05 "An Investigation into the "World-to-chip" Interface", Sammy
S. Datwani, Ph.D, Labcyte Inc., datwani at 

Abstract:  Two arenas of the "World-to-chip" interface will be discussed
with relevant applications to nanoscale biotechnology.  In the first
half of this presentation - a novel micro-fluidic interconnector system
will be discussed that is capable of holding high pressure (up to 7,000
psi) for a fully integrated chip based micro-fluidic high pressure
liquid chromatography (HPLC) system.  Technical aspects of the
interconnect system, design, materials and utility will be discussed.
In the second half of this presentation - a newly developed method,
acoustic droplet ejection (ADE) for precisely generating nanoliter and
picoliter volume droplets using focused acoustic energy at, or near, a
liquid surface will be discussed.  Since both micro-fluidic devices and
micro-plate wells are compatible with this method - a wide range of
experimental results will be shown to elucidate how ADE enables precise
dispensing of small fluid volumes into the "micro and nano" world to aid
in drug discovery and improve experimental results in biochemistry. 

3:05-3:30 Break

3:30-4:00 "Biophysics: Looking forward from the past", S. Jeffrey
Rosner, Ph.D, 

Agilent Technologies, jeff_rosner at

Abstract:  The field of biophysics has been responsible for a large
number of the biology-related Nobel prizes in the 20th century, yet the
promise of quantitative, deterministic measurements in the biological
sciences is only slowly beginning to take hold. This talk will discuss
some of the reasons behind this and show examples of some of the most
exciting current research in biological measurements deriving from the
physics community.

4:00-4:30 "Transdermal delivery of macromolecules using Macroflux(r)
technology - system requirements with emphasis on microfabrication,
surface chemical properties, drug-specific requirements, and the
interaction with human skin and systemic biology", 

Russell Ford, Ph.D, Zosano Pharma, RFord at 

Abstract:  Transdermal drug delivery offers unique advantages compared
to alternate routes such as oral, parenteral, and pulmonary. Transdermal
systems have traditionally been limited to pharmaceuticals with
molecular weight of 500 Daltons or less. Much focus has been centered on
microneedle, microporation, iontophoretic, and other approaches to
increasing the size of candidate drugs that can be transdermally
administered. The Macroflux technology, originally developed by Alza
Corporation, a division of Johnson & Johnson, is at the forefront of
microneedle-based transdermal drug delivery. The basic principle of
operation involves a dynamic mechanical actuator, microfabricated array
of microprojections on an adhesive patch, and special-purpose drug
formulation. This total system addresses the numerous and varied
requirements for a drug delivery system across a wide spectrum of drug
candidates. This presentation outlines the numerous disciplines and
technology elements necessary to ensure the total system functions as
intended. Special emphasis will be placed on the roles of
microfabrication, surface chemical properties, drug-specific
requirements, and the interaction with human skin and systemic biology.

4:30 - 5:00 "Micro stereolithography system for 3D micro modeling",
Norihiko Saitou, JSR Corporation, Norihiko_Saitou at 

Abstract:  ACCULAS, developed by D-MEC Co., Ltd. is the world's first
industrial micro stereolithography technology which can create
micro-structures with resolution down to 1um. A large variety of 3D
items such as curved shapes, air bridge structures, overhang structures
and so on, can be created with a singular process by using ACCULAS.
Sample applications include simulation modeling of micro machines, micro
arrays, probe pins and other micro devices. Also, with the addition of
surface metal deposition, the master form can be used as a mold and can
be used to create replicas of itself.  We will introduce the features of
the micro stereolithography equipment ACCULAS and provide a number of
modeling examples. (D-MEC is wholly-owned subsidiary of JSR

Speaker Biographies:

Dr. M. Meyyappan

Meyya Meyyappan is Chief Scientist for Exploration Technology at the
Center for Nanotechnology, NASA Ames Research Center in Moffett Field,
CA.  Until June 2006, he served as the Director of the Center for
Nanotechnology as well as Senior Scientist.  He is a founding member of
the Interagency Working Group on Nanotechnology (IWGN) established by
the Office of Science and Technology Policy (OSTP).  The IWGN is
responsible for putting together the National Nanotechnology Initiative.
Dr. Meyyappan has authored or co-authored over 175 articles in peer
reviewed journals and made over 200 Invited/Keynote/Plenary Talks in
nanotechnology subjects across the world.  His research interests
include carbon nanotubes and various inorganic nanowires, their growth
and characterization, and application development in chemical and
biosensors, instrumentation, electronics and optoelectronics. Dr.
Meyyappan is a Fellow of the Institute of Electrical and Electronics
Engineers (IEEE), the Electrochemical Society (ECS), AVS, Materials
Research Society, and the California Council of Science and Technology.
In addition, he is a member of the American Society of Mechanical
Engineers (ASME) and American Institute of Chemical Engineers.  He is
the IEEE Nanotechnology Council Distinguished Lecturer on
Nanotechnology, IEEE Electron Devices Society Distinguished Lecturer,
and ASME's Distinguished Lecturer on Nanotechnology (2004-2006).  He
served as the President of the IEEE's Nanotechnology Council in
2006-2007. For his contributions and leadership in nanotechnology, he
has received numerous awards including: a Presidential Meritorious
Award; NASA's Outstanding Leadership Medal; Arthur Flemming Award given
by the Arthur Flemming Foundation and the George Washington University;
2008 IEEE Judith Resnick Award; IEEE-USA Harry Diamond Award; AIChE
Nanoscale Science and Engineering Forum Award.  For his sustained
contributions to nanotechnology, he was inducted into the Silicon Valley
Engineering Council Hall of Fame in February 2009.  For his educational
contributions, he has received:  Outstanding Recognition Award from the
NASA Office of Education; the Engineer of the Year Award(2004) by the
San Francisco Section of the American Institute of Aeronautics and
Astronautics(AIAA); IEEE-EDS Education Award.


Demir Akin, D.V.M, Ph.D.

Dr. Demir Akin is and internationally recognized expert in
Nanobiotechnology and a pioneer nanomedical scientist in the areas of
bioinspired diagnostic and therapeutic devices and their applications in
cancer as well as infectious diseases. His formal education includes a
doctorate in veterinary medicine, a master's in clinical and diagnostic
microbiology and a doctorate in comparative pathobiology and molecular
virology. Most recently he was at the Biomedical Engineering Department
at Purdue University as an assistant research professor (Nanomedicine)
and there he also managed the BioMEMS and Nanobio laboratories of the
Birck Nanotechnology Center. He currently serves as the Deputy Director
of the Center for Cancer Nanotechnology Excellence focused on Therapy
Response (CCNE-TR) in the School of Medicine at Stanford University. Dr.
Akin worked in the areas of molecular virology and viral bioinformatics
of coronaviruses and other RNA viruses from 1998 to 2000 for his
postdoctoral work at Purdue University. He became a Research Scientist
in the School of Nuclear Engineering at Purdue University in 2001 and
worked on artificial intelligence-based In-Silico Biology and Genomics
software development with a cancer focus. He joined the Electrical and
Computer Engineering Department at Purdue University in 2002 as a Senior
Research Scientist and the Manager of the BioMEMS Laboratories. He was
instrumental in the ground-up design, operation and leadership of the
Birck Nanotechnology Center at Purdue and served as the Manager of the
BioMEMS and Nanobio Laboratories from 2003 to 2008. Among other
responsibilities at Birck, he instructed formal Nanobio and BSL-2
training to the shared facility users, provided biomedical expertise to
the engineering research groups and he was responsible for the
compliance assurances for federal, state and institutional regulations
and biocontainment/biosafety practices. Dr. Akin carried out research in
the areas of diagnostic and therapeutic micro/nano-medical devices,
microchip and microfluidics-based devices for biothreat agent detection,
nanomedical robotics via biomimetic devices, biosensing and single
molecule imaging studies of biological entities at nanomaterials
interfaces and biological engineering for synthetic biology during his
Research Assistant Professor appointment at the Weldon School of
Biomedical Engineering at Purdue. Among his other distinctions, he is a
founding member of the American Academy of Nanomedicine, a member of NCI
Alliance for Nanotechnology in Cancer and serves as panelist on numerous
grant/scientific review boards nationally and internationally. His
research interests include integration of biology and engineering for
realization of biomimetic and bioinspired medical devices, Nanomedicine
(BioMEMS-based sensors and devices with medical diagnostic and
therapeutic potential, early cancer detection and antineoplastic therapy
response monitoring, smart nanodrugs and their targeted delivery and
controlled release), synthetic biology, single molecule sensing, imaging
and their mechanoelastic/biophysical characterization using atomic force
microscopy, advanced optical microscopy and electro-mechanical sensing,
and infectious agent diagnostics for biothreat agents and viral
pathogens with pandemic potential. 


Sammy S. Datwani, Ph.D.

Dr. Datwani is a Staff Engineer and the Chemistry Department Manager in
the R&D Division of Labcyte Inc., a biotechnology start-up company
located in the bay area.  Dr. Datwani has over fifteen years of
experience managing & applying cutting edge research and development in
industry & academia.  Dr. Datwani's research interests include an
in-depth understanding of fluid mechanics, interfacial transport,
surface chemistry, thin films, microfluidics, microdevice design,
laboratory automation, high throughput drug screening, microarraying,
polymer chemistry and materials science.  Prior to joining Labcyte, Dr.
Datwani was the technical lead for the development of an integrated high
performance liquid chromatography on a chip (cHiPLCTM) system in the
Advanced Development Group at Eksigent Technologies, LLC.  Prior to
that, Dr. Datwani led the development of the Library CardTM product
which married high throughput drug discovery on a microfluidic chip with
a high density reagent storage array.  Dr. Datwani earned his Ph.D. in
Chemical and Biomolecular Engineering from The Johns Hopkins University
and a M.S. in Chemical Engineering and Polymer Science from The Columbia


S. Jeffrey Rosner, Ph.D.

After a several opportunities with startups, government, and other
corporations, Jeff Rosner joined Hewlett-Packard (HP) in 1978. There he
has held a variety of management and individual contributor positions in
operating divisions and the corporate laboratories. When Agilent was
formed from the instrumentation core of HP's business, Jeff joined the
new company, where he has been deeply involved in technology
acquisition. He has authored or co-authored over 50 journal articles and
holds 13 U.S. patents. He holds a BS in Electrical Engineering from the
Massachusetts Institute of Technology and an MS and Ph.D. from Stanford
University in Materials Science.


Russell Ford, Ph.D.

Russell Ford has been at Zosano Pharma (formerly The Macroflux
Corporation) since 2006 as Associate Director System Design and
Development, responsible for design, integration, and manufacturability
of non-drug components including the microprojection array, applicator,
adhesive patch, and primary packaging. During this time, numerous design
improvements have been implemented that increase drug delivery payload,
manufacturability of the array, ease-of-use, and patient compliance.
Prior to Zosano, he spent over 6 years at Cygnus Therapeutics, working
on the GlucoWatch, the first-ever FDA approved automatic semicontinuous
glucose monitoring system. Using reverse iontophoresis, the devise
implemented a disposable hydrogel and screen-printed electrodes to
sample interstitial fluid through the skin. He has also designed
minimally invasive neurovascular intervention products at Boston
Scientific. Prior to this medical device experience, he has worked on a
variety of manufacturing technologies, including some time with Applied
Materials on their robotic mechanisms for wafer processing equipment.
Dr. Ford earned his Masters and PhD degrees in Mechanical
Engineering/Design Division at Stanford University.


Norihiko Saitou

Mr. Norihito Saitou graduated from Keio University Japan at 1988. After
that He got the master degree at 1990 from Keio University and joined to
JSR corporation immediately. He worked in JSR research center around
5years to develop the UV curable resin development. After that, until
now, he has been managing business of this UV curable resin in JSR


Corporate Sponsorship Opportunities for TFUG Meetings!  
For details please contact meeting Co-Chairs listed above or Heather
Korff, NCCAVS Office, 
530-896-0477, heather at


2009 TFUG Meeting Schedule: (
<>  - Dates/location subject to change)

All Meetings at SEMI Global Headquarters, unless otherwise indicated.


August 19-Display (Image/OELD/LED), submit abstracts to Co-Chairs, Qian
Wang, Edith Ong, and Ketan Itchhaporia, qwang at,
edithong at, gkfly at 

November 8-13-AVS 56th International Symposium & Exhibition, San Jose,
CA.  For details visit <> 


December 9-BEOL Integration, submit abstracts to Co-Chairs: 
Brett Cruden, Roc Blumenthal, and Kapila Wijekoon; bcruden at,
roc at, kapila_wijekoon at


NCCAVS User Group website:

Find: Meeting Schedules, Announcements, Call for Papers, Committee
Contact Information, Proceedings from monthly meetings, and more.

Sign up for a User Group:





More information about the labmembers mailing list